Randomized comparison of 9-month stent strut coverage of
biolimus and everolimus drug-eluting stents assessed by optical
coherence tomography in patients with ST-segment elevation
myocardial infarction. Long-term (5-years) clinical follow-up
(ROBUST trial)

J 2023

Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)

JAKL, Martin; Pavel CERVINKA; Jan KAŇOVSKÝ; Petr KALA; Martin POLOCZEK et al.

Základní údaje

Originální název

Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)

Autoři

JAKL, Martin; Pavel CERVINKA; Jan KAŇOVSKÝ; Petr KALA; Martin POLOCZEK; Michaela CERVINKOVA; Hiram G BEZERRA; Zdenek VALENTA a Marco Aurelio COSTA

Vydání

CARDIOLOGY JOURNAL, GDANSK, VIA MEDICA, 2023, 1897-5593

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Polsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.500

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00133406

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

drug-eluting stent; primary percutaneous coronary intervention; stent strut coverage; optical coherence tomography; ST-segment elevation myocardial infarction; clinical trials

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 2. 2024 09:51, Mgr. Tereza Miškechová

Anotace

V originále

Background: The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Nine-month clinical and angiographic data were also compared in both groups as well as clinical data at 5 years of follow-up.Methods: A total of 201 patients with STEMI were enrolled in the study and randomized either to pPCI with BES or EES implantation. All patients were scheduled for 9 months of angiographic and OCT follow-up.Results: The rate of major adverse cardiovascular events (MACE) was comparable at 9 months in both groups (5% in BES vs. 6% in the EES group; p = 0.87). Angiographic data were also comparable between both groups. The main finding at 9-month OCT analysis was the greatly reduced extent of mean neointimal area at the cost of a higher proportion of uncovered struts in the BES group (1.3 mm2 vs. 0.9 mm2; p = 0.0001 and 15.9% vs. 7.0%; p = 0.0001, respectively). At 5 years of clinical follow-up the rate of MACE was comparable between both groups (16.8% vs. 14.0%, p = 0.74).Conclusions: The study demonstrates a very low rate of MACE and good 9-month stent strut coverage of second-generation BES and EES in patients with STEMI. BES showed greatly reduced extent of mean neointimal hyperplasia area at the cost of a higher proportion of uncovered struts when compared to EES. The rate of MACE was low and comparable in both groups at 5 years. (Cardiol J 2023; 30, 6: 921-928)

Citovat

JAKL, Martin; Pavel CERVINKA; Jan KAŇOVSKÝ; Petr KALA; Martin POLOCZEK; Michaela CERVINKOVA; Hiram G BEZERRA; Zdenek VALENTA a Marco Aurelio COSTA. Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial). CARDIOLOGY JOURNAL. GDANSK: VIA MEDICA, 2023, roč. 30, č. 6, s. 921-928. ISSN 1897-5593. Dostupné z: https://doi.org/10.5603/CJ.a2023.0013.

@article{2368963,
   author = {Jakl, Martin and Cervinka, Pavel and Kaňovský, Jan and Kala, Petr and Poloczek, Martin and Cervinkova, Michaela and Bezerra, Hiram G and Valenta, Zdenek and Costa, Marco Aurelio},
   article_location = {GDANSK},
   article_number = {6},
   doi = {https://doi.org/10.5603/CJ.a2023.0013},
   keywords = {drug-eluting stent; primary percutaneous coronary intervention; stent strut coverage; optical coherence tomography; ST-segment elevation myocardial infarction; clinical trials},
   language = {eng},
   issn = {1897-5593},
   journal = {CARDIOLOGY JOURNAL},
   title = {Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)},
   url = {https://journals.viamedica.pl/cardiology_journal/article/view/90905},
   volume = {30},
   year = {2023}
}

TY  - JOUR
ID  - 2368963
AU  - Jakl, Martin - Cervinka, Pavel - Kaňovský, Jan - Kala, Petr - Poloczek, Martin - Cervinkova, Michaela - Bezerra, Hiram G - Valenta, Zdenek - Costa, Marco Aurelio
PY  - 2023
TI  - Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)
JF  - CARDIOLOGY JOURNAL
VL  - 30
IS  - 6
SP  - 921-928
EP  - 921-928
PB  - VIA MEDICA
SN  - 18975593
KW  - drug-eluting stent
KW  - primary percutaneous coronary intervention
KW  - stent strut coverage
KW  - optical coherence tomography
KW  - ST-segment elevation myocardial infarction
KW  - clinical trials
UR  - https://journals.viamedica.pl/cardiology_journal/article/view/90905
N2  - Background: The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Nine-month clinical and angiographic data were also compared in both groups as well as clinical data at 5 years of follow-up.Methods: A total of 201 patients with STEMI were enrolled in the study and randomized either to pPCI with BES or EES implantation. All patients were scheduled for 9 months of angiographic and OCT follow-up.Results: The rate of major adverse cardiovascular events (MACE) was comparable at 9 months in both groups (5% in BES vs. 6% in the EES group; p = 0.87). Angiographic data were also comparable between both groups. The main finding at 9-month OCT analysis was the greatly reduced extent of mean neointimal area at the cost of a higher proportion of uncovered struts in the BES group (1.3 mm2 vs. 0.9 mm2; p = 0.0001 and 15.9% vs. 7.0%; p = 0.0001, respectively). At 5 years of clinical follow-up the rate of MACE was comparable between both groups (16.8% vs. 14.0%, p = 0.74).Conclusions: The study demonstrates a very low rate of MACE and good 9-month stent strut coverage of second-generation BES and EES in patients with STEMI. BES showed greatly reduced extent of mean neointimal hyperplasia area at the cost of a higher proportion of uncovered struts when compared to EES. The rate of MACE was low and comparable in both groups at 5 years. (Cardiol J 2023; 30, 6: 921-928)
ER  -

JAKL, Martin; Pavel CERVINKA; Jan KAŇOVSKÝ; Petr KALA; Martin POLOCZEK; Michaela CERVINKOVA; Hiram G BEZERRA; Zdenek VALENTA a Marco Aurelio COSTA. Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial). \textit{CARDIOLOGY JOURNAL}. GDANSK: VIA MEDICA, 2023, roč.~30, č.~6, s.~921-928. ISSN~1897-5593. Dostupné z: https://doi.org/10.5603/CJ.a2023.0013.

Přehled o publikaci